Risk factors and consequences of post‐transplant diabetes mellitus

Demirci, Meltem Seziş; Töz, Hüseyin; Yılmaz, Fi̇li̇z Kızılırmak; Ertilav, Muhittin; Aşçı, Gülay; Özkahya, Mehmet; Zeytinoğlu, Ayşın; Nart, Denız; Ok, Ercan

doi:10.1111/j.1399-0012.2010.01247.x

Cited by 45 publications

(37 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Kidney transplant recipients diagnosed with NODAT are at higher risk of CVD [17,30]. Much like pre-transplant diabetes, NODAT confers 2 to 3 times the risk for cardiac events after transplant [31,32].…”

Section: New-onset Diabetes After Transplant (Nodat)mentioning

confidence: 99%

Diabetes and Cardiovascular Disease Following Kidney Transplantation

Boerner¹,

Shivaswamy²,

Desouza³

et al. 2011

CDR

View full text Add to dashboard Cite

Kidney transplantation is being performed more frequently for individuals with end stage renal disease (ESRD) due to improved survival and quality of life compared to long-term dialysis. Though rates decrease after transplant, cardiovascular disease (CVD) remains the most common cause of death after kidney transplant. New-onset diabetes after transplant (NODAT), a common complication following kidney transplantation, and pre-transplant diabetes both significantly increase the risk for CVD. Several other risk factors for CVD in kidney transplant recipients have been identified; however, optimal therapy for controlling the risk factors of CVD after kidney transplantation, including NODAT and pretransplant diabetes, is not well defined. In the following review we will discuss the role of traditional and non-traditional risk factors in CVD after kidney transplant and the mechanisms involved therein. We will also examine the current literature regarding treatment of these risk factors for the prevention of CVD. Finally, we will review the current recommendations for pre-and post-transplant cardiovascular evaluation and management.

show abstract

Section: New-onset Diabetes After Transplant (Nodat)mentioning

confidence: 99%

Diabetes and Cardiovascular Disease Following Kidney Transplantation

Boerner¹,

Shivaswamy²,

Desouza³

et al. 2011

CDR

View full text Add to dashboard Cite

show abstract

“…25 Risk factors for PTDM after RT include increased age, black ethnicity, hepatitis C infection, and concomitant administration of high doses of steroids. 26 Neurotoxicity due to tacrolimus can range from mild symptoms such as headache and tremor to more severe effects such as seizures, delirium, and coma. Posterior reversible encephalopathy syndrome is a serious complication of tacrolimus therapy, which is due to reversible vasogenic edema of subcortical white matter and can lead to irreversible cytotoxic edema with significant morbidity and mortality.…”

Section: Adverse Effectsmentioning

confidence: 99%

Untitled

Shrestha

2017

Exp Clin Transplant

View full text Add to dashboard Cite

Tacrolimus, a calcineurin inhibitor, has been the cornerstone of immunosuppressive regimens in renal transplant over 2 decades. This has significantly improved the outcomes of renal transplant, including reduction of acute rejection episodes, improvement of renal function and graft survival, and reduction of some of the adverse effects associated with cy closporine. However, use of tacrolimus is associated with a number of undesirable effects, such as nephrotoxicity, posttransplant diabetes mellitus, neurotoxicity, and cosmetic and electrolyte disturbances. To alleviate these effects, several strategies have been adopted to minimize or eliminate tacrolimus from maintenance regimens of immuno suppression, with some success. This review focuses on advancements in the under standing of the basic science related to tacrolimus and the clinical evidences that have examined the efficacy and safety of tacrolimus in renal transplant over the past 2 decades and highlights the future directions.

show abstract

“…Elle est noté e chez les transplanté s hé patiques [49] comme chez les greffé s ré naux dans de nombreux travaux [49][50][51][52][53]. Cette association n'est cependant pas retrouvé e dans une é tude où 12 856 transplanté s ré naux ont é té é valué s prospectivement entre 1989 et 2002 dans 37 pays (Multinational Observational Study in Transplantation) jusqu'à cinq ans aprè s la greffe [54].…”

Section: Virus De L'he´patite C Et Diabe`te Apre`s Transplantation Reunclassified